

TABLE OF CONTENTS
BIOLOGICALS BEYOND 2000

**SESSION I: THE FUTURE OF BIOLOGICAL STANDARDISATION:
HOW TO PREPARE A WORLDWIDE COMMON APPROACH**

European regulatory policies and perspectives in the biological field Mr. F. Sauer , Executive Director, European Agency for the Evaluation of Medicines (EMA), London (UK)	13
European industry approaches Dr. A. M. Georges , European Federation of Pharmaceutical Industries' Associations (EFPIA), Brussels (B)	19

**SESSION II: RECENT DEVELOPMENTS IN GENETICS:
QUALITY ISSUES FROM PRODUCTION TO CONTROL**

The use of gene medicines to create novel pharmacological responses Dr. E. Tomlinson , The Scientific World, The Woodlands (USA)	29
Quality control of adenovirus vectors for gene therapy D. Malarme, PhD , Transgene, Strasbourg (F)	41
Production of biopharmaceuticals from transgenic animals A.E. Kuta, PhD , Regulatory Affairs, Genzyme Corporation, Framingham (USA)	51
Transgenic mice bearing human poliovirus receptor for quality control T. Iwasaki, PhD , Dpt of Virology, National Institute of Infectious Diseases, Tokyo (J)	59
DNA vaccines: development and standardisation of nucleic acid vaccines Prof. Dr. K. Cichutek , Head, Department of Medical Biotechnology, Paul-Ehrlich-Institut, Langen (D)	69
Particle-mediated delivery of DNA vaccines Dr. J. Faulkner , Section Head, Glaxo Wellcome R&D, Beckenham (UK)	

**SESSION III: GENERAL METHODS FOR CHARACTERISATION OF
BIOLOGICALS — FUTURE TOOLS FOR BIOLOGICAL STANDARDISATION**

Current analytical procedures for glycosylated proteins T. Hayakawa, PhD , NIHS, Tokyo (J)	87
Rapid, sensitive, HPLC-based sequencing strategies for N- and O-linked oligosaccharides attached to 5-20 micrograms of glycoproteins Dr. P. M. Rudd , Oxford Glycobiology Institute, Oxford (UK)	103
NMR identity tests for polysaccharides used in vaccines: methods and validation Dr. C. Jones , Laboratory for Molecular Structure, NIBSC, Potters Bar (UK)	119

The application of NMR spectroscopy to track the industrial preparation of polysaccharide and derived glycoconjugate vaccines
Dr. N. Ravenscroft, Chiron Spa, Sienna (I) 131

Surface plasmon resonance as a tool for viral vaccine characterization
Dr. M. Washabaugh, Merck, West Point (USA) 145

A Canadian perspective on assessing comparability of biotechnology products
Dr. A. Ridgway, Bureau of Biologics & Radiopharmaceuticals, Health Canada, Ottawa (C) 147

**SESSION IV: SAFETY ISSUES: HOW TO MINIMISE THE RISKS
IN THE DEVELOPMENT OF BIOLOGICAL PRODUCTS**

Nucleic acid amplification tests: current status, advances in techniques and new applications
Dr. M. Nübling, Paul-Ehrlich-Institut, Langen (D) 165

Immunogenicity of therapeutic cytokines
Dr. M. Wadhwa, Division of Immunobiology, NIBSC, Potters Bar (UK) 177

SESSION V: VACCINES: NEW ISSUES FOR QUALITY AND CONTROL

Mucosal delivery of influenza vaccines
Dr. R. Glück, Swiss Serum & Vaccine Institute, Bern (CH) 193

A murine model for control and new developments in pertussis vaccination
Prof. K. Mills, Department of Biology, National University of Ireland, Maynooth (IRL) 205

Recent developments in the characterisation of pneumococcal conjugate vaccines
Dr. M. Moreau, Research Department Pasteur Mérieux Connaught, Marcy l'Etoile (F) 211

Quality control of protein-polysaccharide conjugate vaccines
W. Egan, PhD, Office of Vaccines, CBER, (FDA), Rockville (USA) 221

SESSION VI: BLOOD PRODUCTS

Development of recombinant DNA albumin: character and its quality challenge
Dr. K. Kobayashi, Senior Researcher, Osaka Laboratories, Bioscience Research Division, Yoshitomi Pharmaceutical Industries, Osaka (J) 229

Recombinant blood coagulation factors: development of recombinant human factor IX (BeneFIX®)
H. A. Scoble, PhD, Genetics Institute, Andover (USA) 239

SESSION VII: STANDARDISATION AND REGULATORY ISSUES

Round-table discussion with the participation of the The Food and Drug Administration (FDA); the European Agency for the Evaluation of Medicinal Products (EMEA); the National Institute of Health Sciences (NIHS); the European Pharmacopoeia; the Japanese Pharmacopoeia; the United States Pharmacopoeia and Industries. 259

SATELLITE SYMPOSIUM ON VETERINARY BIOLOGICALS
SESSION I: ENSURING QUALITY AND SAFETY

European approach to ensuring quality Miss M. Leivers , Veterinary Products Unit, EMEA, London (UK)	289
United States approach Dr. R. Schnurr , United States Department of Agriculture (USDA), Ames (USA)	297
Quality control system of veterinary biological products in Japan O. Itoh, DVM, MS, PhD , Ministry of Agriculture, Forestry and Fisheries (MAFF), Tokyo (J)	305
Towards international harmonisation C. Verschueren , Confédération Mondiale de l'Industrie de la Santé Animale (COMISA), Brussels (B)	311
Current industry concerns Dr. K. McClure , Animal Health Institute (AHI), Washington D.C. (USA)	317
International harmonisation: viewpoint of the European industry Dr. S. Zänker , Fedesa, Brussels (B)	319

SESSION II: EXTRANEEOUS AGENTS TESTING

Testing for extraneous viruses Dr. C. Folkers , Fedesa, Brussels (B)	327
The extraneous virus test for veterinary biological products in Japan O. Itoh, DVM, MS, PhD , Ministry of Agriculture, Forestry and Fisheries (MAFF), Tokyo (J)	335

SESSION III: TARGET ANIMAL SAFETY TEST

Is there still a need for the target animal safety test beyond 2000? Dr. K. Cussler , Paul-Ehrlich-Institut, Langen (D)	343
Specifications of animals for safety testing Dr. B. Roberts , FEDESA Biologicals Working Party, Brussels (B)	349

SESSION IV: POTENCY TESTING

Efficacy testing: the European approach to fill in trials Prof. P-P. Pastoret , Immunological Working Party, EMEA, London (UK)	355
Validity and consistency: the 21 st century approach to effective potency assurance R. Lucken , Registration and QA Consultant in Veterinary Vaccines, Trawsant, Llandysul (UK)	361

Standards and guidelines for conducting *in vitro* enzyme immunoassays for relative antigen content of veterinary biological products in the United States
Dr. R.E. Hill Jr., Center for Veterinary Biologics, Licensing and Policy Development, United States Department of Agriculture (USDA), Ames (USA) 369

SESSION V: REFERENCE PREPARATIONS

The role of reference preparations in the United States
Dr. R. L. Levings, United States Department of Agriculture (USDA), Ames (USA) 375

Optimising the use of reference preparation(s)
Dr. C. Jüngback, Paul-Ehrlich-Institut, Langen (D) 379

SCIENTIFIC POSTER 385

BIOGRAPHICAL NOTES 393

LIST OF PARTICIPANTS 405